REFERENCES
1. Ferlizza E, Solmi R, Sgarzi M, Ricciardiello L, Lauriola M. The roadmap of colorectal cancer screening. Cancers (Basel) 2021;13:1101.
2. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22.
4. Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol 2015;21:11767-76.
5. Valderrama-Treviño AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Javé EE. Hepatic metastasis from colorectal cancer. Euroasian J Hepatogastroenterol 2017;7:166-75.
6. Petrelli F, Coinu A, Lonati V, Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015;30:447-57.
7. Mukkamalla SKR, Huynh DV, Somasundar PS, Rathore R. Adjuvant chemotherapy and tumor sidedness in stage ii colon cancer: analysis of the national cancer data base. Front Oncol 2020;10:568417.
8. Tamura T, Kuwahara A, Kadoyama K, et al. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8:406-12.
9. Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B. Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. Acta Oncol 1996;35:207-12.
10. Tomlinson SK, Melin SA, Higgs V, et al. Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer - a phase II study. BMC Cancer 2002;2:1-7.
11. Françoso A, Simioni PU. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 2017;11:177-84.
12. Laffer U, Metzger U, Aeberhard P, et al. Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. Int J Colorectal Dis 2008;23:1233-41.
13. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021;325:669-85.
14. Shinozaki E, Makiyama A, Kagawa Y, et al. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: a retrospective observational study using an administrative database. PLoS One 2021;16:e0246160.
15. Köberle B, Schoch S. Platinum complexes in colorectal cancer and other solid tumors. Cancers (Basel) 2021;13:2073.
16. Tomicic MT, Steigerwald C, Rasenberger B, Brozovic A, Christmann M. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6. Arch Toxicol 2019;93:2265-77.
17. Mirakhorli M, Shayanfar N, Rahman SA, Rosli R, Abdullah S, Khoshzaban A. Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy. Oncol Lett 2012;4:893-7.
18. Huang MY, Tsai HL, Lin CH, et al. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol 2013;108:457-64.
19. Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 2017;23:461-71.
21. McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol 2016;7:414.
22. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 2018;47:6645-53.
23. Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther 2015;14:1767-76.
24. Gamberi T, Pratesi A, Messori L, Massai L. Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds. Coord Chem Rev 2021;438:213905.
25. Fernández-moreira V, Herrera RP, Gimeno MC. Anticancer properties of gold complexes with biologically relevant ligands. Pure Appl Chem 2019;91:247-69.
26. Liu W, Gust R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem Soc Rev 2013;42:755-73.
27. Kim JH, Ofori S, Parkin S, Vekaria H, Sullivan PG, Awuah SG. Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition. Chem Sci 2021;12:7467-79.
28. Rigobello MP, Scutari G, Boscolo R, Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 2002;136:1162-8.
29. Citta A, Schuh E, Mohr F, et al. Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. Metallomics 2013;5:1006-15.
30. Gordon AN, Tonda M, Sun S, Rackoff W. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
31. Rackham O, Nichols SJ, Leedman PJ, Berners-Price SJ, Filipovska A. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria. Biochem Pharmacol 2007;74:992-1002.
32. Messori L, Marcon G, Innocenti A, Gallori E, Franchi M, Orioli P. Molecular recognition of metal complexes by DNA: a comparative study of the interactions of the parent complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl2 with double stranded DNA. Bioinorg Chem Appl 2005:239-53.
33. Alsaeedi MS, Babgi BA, Hussien MA, Abdellattif MH, Humphrey MG. DNA-binding and anticancer activity of binuclear gold(I) alkynyl complexes with a phenanthrenyl bridging ligand. Molecules 2020;25:1033.
34. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim) 2007;340:117-26.
36. Shaw CF. . Chrysotherapy:gold-drug metabolism and immunochemistry. In: Clarke MJ, Sadler PJ, editors. Metallopharmaceuticals II. Berlin: Springer Berlin Heidelberg; 1999. p. 187-216.
37. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 2007;42:872-81.
38. Harbut MB, Vilchèze C, Luo X, et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci U S A 2015;112:4453-8.
39. Thangamani S, Maland M, Mohammad H, et al. Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway. Front Cell Infect Microbiol 2017;7:4.
40. Díez-Martínez R, García-Fernández E, Manzano M, et al. Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections. Sci Rep 2016;6:19525.
41. Onodera T, Momose I, Kawada M. Potential anticancer activity of auranofin. Chem Pharm Bull (Tokyo) 2019;67:186-91.
42. Raninga PV, Lee AC, Sinha D, et al. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. Int J Cancer 2020;146:123-36.
43. Menconi A, Marzo T, Massai L, et al. Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles. Biometals 2021;34:867-79.
44. Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K, Crooke ST. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res 1985;45:32-9.
45. Zoppi C, Messori L, Pratesi A. ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. Dalton Trans 2020;49:5906-13.
46. Tolbatov I, Cirri D, Marchetti L, et al. Mechanistic insights into the anticancer properties of the auranofin analog Au(PEt3)I: a theoretical and experimental study. Front Chem 2020;8:812.
47. Hossain MF, Bodnar Y, Klein C, et al. Molecular basis for the interactions of human thioredoxins with their respective reductases. Oxid Med Cell Longev 2021;2021:6621292.
48. Magherini F, Modesti A, Bini L, et al. Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J Biol Inorg Chem 2010;15:573-82.
49. Yue S, Luo M, Liu H, Wei S. Recent advances of gold compounds in anticancer immunity. Front Chem 2020;8:543.
50. Freire Boullosa L, Van Loenhout J, Flieswasser T, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biol 2021;42:101949.
51. Marzo T, Cirri D, Gabbiani C, et al. Auranofin, Et3PAuCl, and Et3PAuI are highly cytotoxic on colorectal cancer cells: a chemical and biological study. ACS Med Chem Lett 2017;8:997-1001.
52. Cirri D, Fabbrini MG, Massai L, et al. Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. Biometals 2019;32:939-48.
53. Marzo T, Pillozzi S, Hrabina O, et al. cis-Pt I2(NH3)2: a reappraisal. Dalton Trans 2015;44:14896-905.
54. Cirri D, Pillozzi S, Gabbiani C, et al. PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. Dalt Trans 2017;46:3311-7.
55. Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ. Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines. Int J Mol Sci 2019;20:3619.
56. Han Y, Chen P, Zhang Y, et al. Synergy between Auranofin and Celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism. Cancers (Basel) 2019;11:931.
57. Bradley C, Yabroff KR, Warren JL, Chawla N, Zeruto C, Lamont EB. Trends in chemotherapy-related treatment of advanced-stage colorectal (CRC) cancer. J Clin Oncol 2013;31:258-258.
58. Arena S, Corti G, Durinikova E, et al. A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. Clin Cancer Res 2020;26:1372-84.
